Seven Fleet Capital Management LP Buys New Stake in SAB Biotherapeutics, Inc. $SABS

Seven Fleet Capital Management LP purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 500,000 shares of the company’s stock, valued at approximately $1,915,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SABS. Vivo Capital LLC acquired a new stake in SAB Biotherapeutics during the third quarter valued at approximately $22,954,000. Perceptive Advisors LLC raised its holdings in shares of SAB Biotherapeutics by 700.8% in the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock worth $24,634,000 after buying an additional 5,628,533 shares in the last quarter. RA Capital Management L.P. acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter worth approximately $8,847,000. Woodline Partners LP bought a new position in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $5,730,000. Finally, Spruce Street Capital LP bought a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $8,222,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Trading Up 0.3%

Shares of SABS opened at $3.57 on Friday. The stock’s fifty day simple moving average is $3.67 and its 200-day simple moving average is $3.83. The firm has a market capitalization of $272.96 million, a PE ratio of -1.69 and a beta of 0.52. SAB Biotherapeutics, Inc. has a 12-month low of $1.85 and a 12-month high of $5.15. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). As a group, research analysts predict that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wall Street Zen cut SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. Rodman & Renshaw reiterated a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, May 11th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of SAB Biotherapeutics in a report on Monday, June 15th. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Jefferies Financial Group began coverage on shares of SAB Biotherapeutics in a report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.